Search

Displaying results 3131 - 3140 of 4188 in total
  1. Drug

    ST101 peptide

    go.drugbank.com/drugs/DB17272
    Experimental

    ST101 is a cell-penetrating peptide that disrupts the protein-protein interactions driving ATF5-regulated gene transcription.

  2. Drug

    RP-A601

    go.drugbank.com/drugs/DB18339
    Investigational

    RP-A601 is an adeno-associated virus serotype rhesus 10 vector expressing the human galactocerebrosidase (GALC) gene

  3. Drug

    FBX-101

    go.drugbank.com/drugs/DB18340
    Investigational

    FBX-101 is an adeno-associated virus serotype rhesus 10 vector expressing the human galactocerebrosidase (GALC) gene

  4. Drug

    tgAAG-76

    go.drugbank.com/drugs/DB18421
    Investigational

    tgAAG-76 consists of a recombinant adeno-associated virus (serotype 2) (rAAV2) gene transfer agent expressing RPE65.

  5. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.

  6. Drug

    Etazolate

    go.drugbank.com/drugs/DB05881
    Investigational

    EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.

  7. Drug

    rhIGFBP-3

    go.drugbank.com/drugs/DB05897
    Investigational

    rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of human. It is developed by Insmed...

  8. Drug

    UCB7362

    go.drugbank.com/drugs/DB17096
    Experimental

    UCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria. Plasmepsins are aspartyl proteases produced by the malaria parasite Plasmodium falciparum, and PMX is considered to be essentia...

  9. Drug

    VP025

    go.drugbank.com/drugs/DB05133
    Experimental

    VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation. VP025 may inhibit immune system activation and protect motoneurons from injury. It also shows the abi...

  10. Drug

    KC706

    go.drugbank.com/drugs/DB05157
    Investigational

    KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascula...